The FDA’s proposed PDUFA VIII framework could move manufacturing readiness discussions much earlier in the drug approval process. The plan introduces new CMC facility interactions before submission, stronger communication during inspections and additional engagement after inspection findings. For pharmaceutical sponsors,
